No revenue reported as development-stage programs advanced in key clinical trials. These 10 stocks could mint the next wave of millionaires › PDS Biotechnology (NASDAQ:PDSB), a clinical-stage ...

Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with ...

Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with q ...

A new study published in the Journal of American Medical Association found that Rilzabrutinib decreased itching and hives ...

DelveInsight's Tumor-Infiltrating Lymphocyte Therapies Market Size, Target Population, Competitive Landscape & Market ...

In August 2025, Bayer announced a study of researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the ...

Q: I have Type 2 diabetes, and my doctor insists that I give up beverages with almost all sugar substitutes and stick with water. Can you explain what’s wrong with ...

Key Points Revenue (GAAP) exceeded analyst estimates by 10.2% for Q2 2025, with GAAP net revenue rising to $10.3 million, driven by growth in LOQTORZI sales. Non-GAAP EPS missed expectations at $(0.34 ...

Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.

Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as ...

Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

The Colorectal Cancer Alliance, the American College of Gastroenterology, AGA, and others are encouraging HHS Secretary ...